Kymera Therapeutics Overview. Kymera Therapeutics, Inc. (NASDAQ:KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate ...

Potential Positives. Phase 1 healthy volunteer data of KT-621 demonstrated >90% mean STAT6 degradation in blood across all doses above 1.5 mg, exceeding company targets and suggesting strong efficacy.

Deputy Editor Amanda Borschel-Dan is the host of The Times of Israel’s Daily Briefing, What Matters Now and Friday Focus podcasts and heads up The Times of Israel’s features.

General Dynamics got $621.0 million added to a contract with the U.S. Army. The funding is for General Dynamics Land Systems to work on SGT Stout systems and services in Sterling Heights, Mich ...

KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation.

His drive never flatlined. Michael Dowling, the outgoing CEO of Northwell Health, has revealed in detail to The Post how he went from janitor to helping to build a behemoth system of 28 tri-state ...

The Directorate of School Education has identified as many as 621 schools, primary to senior secondary, for de-notification, merger and downgrading due to zero or negligible enrolment. Education ...

KT-621 is currently being evaluated in a Phase 1b trial (BroADen) in atopic dermatitis patients, with data from the study expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b ...

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like ...

Brandon Pleshek, 38, is a third-generation janitor who boasts decades of experience in the cleaning industry, having grown up around his grandfather's cleaning business, before officially joining ...

KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorption was demonstrated with a median t max of 2-4 hours and a mean half-life of 9-36 hours. There was a ...

On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.